Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSBRUW)

Drug Name

Decamethonium Drug Info

Synonyms

Decamethonum; Syncurine; DECAMETHONIUM ION; AIDS351484; AIDS-351484; Decamethylenebis(trimethylammonium)bromide; Syncurine (TN); Syncurine (*dibromide salt*); Trimethyl-[10-(trimethylazaniumyl)decyl]azanium; C 10 (VAN) (*dibromide salt*); N,N,N,N',N',N'-hexamethyldecane-1,10-diaminium; (DM)Br2; 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-(9CI); 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-, dibromide

Indication

Disease Entry	ICD 11	Status	REF
Muscle spasm	MB47.3	Approved	[1]

Therapeutic Class

Neuromuscular Depolarizing Agents

Cross-matching ID

PubChem CID: 2968
ChEBI ID: CHEBI:41934
CAS Number: CAS 156-74-1
TTD Drug ID: DMSBRUW

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Affected By Cholinesterase (BCHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[4]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[5]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[6]
Rivastigmine	DMG629M	Alzheimer disease	8A20	Approved	[7]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[8]
Succinylcholine	DM2ET1M	Plasma cell myeloma	2A83.1	Approved	[9]
Ethopropazine	DM0N3L7	Parkinson disease	8A00.0	Approved	[5]
Dimenhydrinate	DM264B3	Meniere disease	AB31.0	Approved	[10]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[11]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neuronal acetylcholine receptor alpha-1 (CHRNA1)	TT54JVQ	ACHA_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Gene/Protein Processing	[3]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 006931.
2	Potency of nondepolarizing muscle relaxants on muscle-type acetylcholine receptors in denervated mouse skeletal muscle.Acta Pharmacol Sin.2010 Dec;31(12):1541-6.
3	The mechanism and benefit of human butyrylcholinesterase activation by what would otherwise be inhibitors. Chem Biol Interact. 2019 Aug 1;308:350-356.
4	Increased organophosphate scavenging in a butyrylcholinesterase mutant. Chem Biol Interact. 2008 Sep 25;175(1-3):376-9. doi: 10.1016/j.cbi.2008.04.012. Epub 2008 Apr 22.
5	Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. Arch Biochem Biophys. 2008 Oct 15;478(2):201-5.
6	Lichens of parmelioid clade as promising multitarget neuroprotective agents. Chem Res Toxicol. 2019 Jun 17;32(6):1165-1177.
7	Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7.
8	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9	Response of the newborn to succinlycholine injection in homozygotic atypical mothers. Anesthesiology. 1975 Jul;43(1):115-6. doi: 10.1097/00000542-197507000-00028.
10	Cholinesterase inhibition by phenothiazine and nonphenothiazine antihistaminics: analysis of its postulated role in synergizing organophosphate toxicity. Toxicol Appl Pharmacol. 1975 Feb;31(2):179-90.
11	Qualitative defects of pseudocholinesterase activity. Anaesthesia. 1967 Jan;22(1):55-68.